Основная статистика
| LEI | 549300V1JXXVXU7P8007 |
| CIK | 1624326 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PAVmed Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| August 14, 2025 |
Exhibit 99.1 PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million, and secured CAC meeting on Medicare LCD for EsoGuard to be held on September 4 Veris Health completed 2Q25 financing, relaunched development of implantable physiological monitor, and initiated integration steps to launch comm |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 PAVMED INC. |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2025 PAVMED INC. |
|
| July 28, 2025 |
Calculation of Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Common Stock, $0.001 par value per |
|
| July 28, 2025 |
As filed with the Securities and Exchange Commission on July 28, 2025 As filed with the Securities and Exchange Commission on July 28, 2025 Registration No. |
|
| June 24, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2025 PAVMED INC. |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2025 PAVMED INC. |
|
| May 15, 2025 |
Exhibit 99.1 PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer cen |
|
| May 15, 2025 |
Pre-Funded Warrants, dated February 21, 2025. Exhibit 10.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK PAVMED INC. Warrant Shares: Issue Date: February 21, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exer |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 PAVMED INC. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| May 15, 2025 |
Registration Rights Agreement, dated February 21, 2025. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of the date set forth on the Company’s signature page hereto (the “Effective Date”) between PAVmed Inc., a Delaware corporation (the “Company”), and the persons who have executed a signature page hereto (each, a “Purchaser” and collectively, the “Purchasers”). Unle |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 25, 2025 |
Exhibit 16.1 April 25, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by PAVmed Inc. under Item 4.01 of its Form 8-K dated April 25, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of PAVmed Inc. contained therein. Very truly |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 23, 2025 PAVMED INC. |
|
| April 21, 2025 |
PAVmed Inc. 3,331,084 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-283994 PROSPECTUS PAVmed Inc. 3,331,084 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time of 3,331,084 shares of our common stock, par value $0.001 per share, by the selling stockholders identified in “Selling Stockholders” below. In February 2025, we sold 2,574,350 shares of our common stock and p |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 17, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-283994 PROSPECTUS SUPPLEMENT (to Prospectus dated April 15, 2025) Up to $2,880,000 Common Stock We have entered into a Sales Agreement, or the “sales agreement,” with Maxim Group LLC, or “Maxim,” relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying base prospectus. In acc |
|
| April 17, 2025 |
Exhibit 1.1 Execution Version PAVMED INC. Shares of Common Stock (par value $0.001 per share) Sales Agreement April 17, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: PAVmed Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Maxim Group LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Compa |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2025 PAVMED INC. |
|
| April 15, 2025 |
PAVmed Inc. 360 Madison Avenue, 25th Floor New York, New York 10017 PAVmed Inc. 360 Madison Avenue, 25th Floor New York, New York 10017 April 15, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin Re: PAVmed Inc. Registration Statement on Form S-3 Filed April 8, 2025 File No. 333-286442 Ladies and Gentleme |
|
| April 11, 2025 |
As filed with the Securities and Exchange Commission on April 11, 2025 As filed with the Securities and Exchange Commission on April 11, 2025 Registration No. |
|
| April 11, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2025 PAVMED INC. |
|
| April 11, 2025 |
PAVmed Inc. 360 Madison Avenue, 25th Floor New York, New York 10017 April 11, 2025 PAVmed Inc. 360 Madison Avenue, 25th Floor New York, New York 10017 April 11, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Juan Grana Re: PAVmed Inc. Registration Statement on Form S-3 File No. 333-283994 Ladies and Gentlemen: PAVmed Inc. hereby req |
|
| April 10, 2025 |
As filed with the Securities and Exchange Commission on April 9, 2025 As filed with the Securities and Exchange Commission on April 9, 2025 Registration No. |
|
| April 8, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) PAVMED INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| April 8, 2025 |
As filed with the Securities and Exchange Commission on April 8, 2025 As filed with the Securities and Exchange Commission on April 8, 2025 Registration No. |
|
| April 8, 2025 |
Form of Registration Rights Agreement (filed herewith). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of the date set forth on the Company’s signature page hereto (the “Effective Date”) between PAVmed Inc., a Delaware corporation (the “Company”), and the persons who have executed a signature page hereto (each, a “Purchaser” and collectively, the “Purchasers”). Unle |
|
| April 8, 2025 |
Form of Subscription Agreement (filed herewith). Exhibit 10.1 SUBSCRIPTION AGREEMENT PAVmed Inc. 360 Madison Avenue 25th Floor New York, New York 10017 Ladies and Gentlemen: 1. Subscription. The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from PAVmed Inc., a Delaware corporation (“PAVmed”) and Veris Health Inc., a Delaware corporation (“Veris” and, together with PAVmed, the “Company”), the |
|
| March 25, 2025 |
Exhibit 99.1 PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2025 PAVMED INC. |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| March 24, 2025 |
Exhibit 21.1 List of Subsidiaries of the Registrant (PAVmed Inc. DE - 47-1214177) Subsidiary Legal Entity Name State of Incorporation Lucid Diagnostics Inc. (82-5488042) Delaware Subsidiary of PAVmed Inc. (Incorporated May 8, 2018) LucidDx Labs Inc. (87-41661458) Delaware - Wholly-Owned Subsidiary of Lucid Diagnostics Inc. (Incorporated November 10, 2021) Veris Health Inc. (87-0983820) Delaware - |
|
| March 24, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, PAVmed Inc. (“PAVmed,” the “Company” or “we,” “us” or “our”) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share; and (ii) |
|
| March 24, 2025 |
Exhibit 19.1 PAVMED INC. INSIDER TRADING POLICY (Amended as of October 27, 2022) The Board of Directors of PAVmed Inc. (“Company”) has adopted this Insider Trading Policy (this “Policy”) for directors, officers, employees and consultants of the Company and its subsidiaries with respect to the trading of the Company’s securities, as well as the securities of publicly-traded companies with whom the |
|
| March 10, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2025 PAVMED INC. |
|
| February 21, 2025 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2025 PAVMED INC. |
|
| February 18, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2025 PAVMED INC. |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. |
|
| January 31, 2025 |
Calculation of Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Common Stock, $0.001 par value per |
|
| January 31, 2025 |
Calculation of Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Common Stock, $0.001 par value per |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2025 PAVMED INC. |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 17, 2025 PAVMED INC. |
|
| January 21, 2025 |
Exhibit 4.1 CERTIFICATE OF DESIGNATIONS OF RIGHTS AND PREFERENCES OF SERIES C CONVERTIBLE PREFERRED STOCK OF PAVMED INC. I, Lishan Aklog, M.D., hereby certify that I am the Chairman of the Board and Chief Executive Officer of PAVmed Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 15, 2025 PAVMED INC. |
|
| January 15, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF PAVMED INC. Pursuant to Section 242 of the General Corporation Law of Delaware The undersigned Chairman of the Board and Chief Executive Officer of PAVmed Inc. (the “Corporation”) does hereby certify: FIRST: The name of the Corporation is PAVmed Inc. SECOND: The Certificate of Incorporation of the Corporation is hereby amended |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| December 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Carry |
|
| December 20, 2024 |
Exhibit 4.5 PAVMED INC., As Issuer, AND , As Trustee INDENTURE DATED AS OF [] [], 20[] SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Indenture 310(a) 7.10 310(b) 7.09; 7.11 310(c) Inapplicable 311(a) 7.14 311(b) 7.14 311(c) Inapplicable 312(a) 5.02(a) 312(b) 5.02(c) 312(c) Inapplicable 313(a) 5.04(a) 313(b) 5.04(b) 313(c) 5.04(a); 5.04(b) |
|
| December 20, 2024 |
As filed with the Securities and Exchange Commission on December 20, 2024 As filed with the Securities and Exchange Commission on December 20, 2024 Registration No. |
|
| December 20, 2024 |
Exhibit 4.4 PAVMED INC., As Issuer, AND [], As Trustee INDENTURE DATED AS OF [] [], 20[] SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Indenture 310(a) 7.10 310(b) 7.09; 7.11 310(c) Inapplicable 311(a) 7.14 311(b) 7.14 311(c) Inapplicable 312(a) 5.02(a) 312(b) 5.02(c) 312(c) Inapplicable 313(a) 5.04(a) 313(b) 5.04(b) 313(c) 5.04(a); 5.04(b) 313 |
|
| December 12, 2024 |
(R1933) / PAVmed Inc. Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Lucid Diagnostics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 54948X 109 (CUSIP Number) Lishan Aklog, M.D. Chairman and Chief Executive Officer, PAVmed Inc. 360 Madison Avenue, 2 |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 29, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2024 PAVMED INC. |
|
| November 21, 2024 |
Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (the “Agreement”) is entered into as of this day of , 2024 (the “Exchange Agreement Date”), by and between PAVmed Inc., a Delaware corporation with offices located at 360 Madison Avenue, 25th Floor, New York, NY 10017 (the “Company”) and the investor signatory hereto (the “Holder”), with reference to the following facts: A. Prior to the date |
|
| November 21, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 20, 2024, is by and among PAVmed Inc., a Delaware corporation with offices located at 360 Madison Avenue, 25th Floor, New York, NY 10017 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyer |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2024 PAVMED INC. |
|
| November 21, 2024 |
Form of Series C Convertible Preferred Stock Certificate of Designations. Exhibit 4.1 CERTIFICATE OF DESIGNATIONS OF RIGHTS AND PREFERENCES OF SERIES C CONVERTIBLE PREFERRED STOCK OF PAVMED INC. I, , hereby certify that I am the Chief Executive Officer of PAVmed Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferred upon the Boar |
|
| November 14, 2024 |
Exhibit 99.1 PAVmed Provides Business Update and Third Quarter 2024 Financial Results Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio State’s James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor Ong |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2024 PAVMED INC. |
|
| November 14, 2024 |
PAVM / PAVmed Inc. / FIRST MANHATTAN CO Passive Investment SC 13G 1 firstmanhattan-pavm093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PAVmed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 70387R403 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| September 23, 2024 |
PAVM / PAVmed Inc. / Dubreville Anthony Michael Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* PAVMED INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 70387R403 (CUSIP Number) August 30, 20 |
|
| September 16, 2024 |
Exhibit 99.2 PAVMED INC. and SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (in thousands except number of shares and per share data - unaudited) For the year ended December 31, 2023 As Reported Lucid Diagnostics Inc. Deconsolidation Pro forma Adjustments Footnotes Pro forma Statements Revenue $ 2,452 $ (2,428 ) $ - $ 24 Operating Expenses: Cost of revenue 6,420 (5,979 ) - 441 Sales a |
|
| September 16, 2024 |
Exhibit 99.1 PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, September 16, 2024 – PAVmed Inc. (Nasdaq: PAVM) (“PAVmed” or the “Company”) a diversified commercial-stage medical technology company, operating in the medical device, diagnostics |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2024 PAVMED INC. |
|
| August 13, 2024 |
Exhibit 99.1 PAVmed Provides Business Update and Second Quarter 2024 Financial Results Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA’s MolDX Program Veris Health actively pursuing financing following launch of pilot program with The Ohio State’s James Cancer Hospital Conference call and webcast to be |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2024 PAVMED INC. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| June 20, 2024 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2024 PAVMED INC. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 PAVMED INC. |
|
| May 14, 2024 |
Exhibit 99.1 PAVmed Provides Business Update and First Quarter 2024 Financial Results Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State’s James Cancer Hospital Conference call and webcast to be held tomorrow, May 14th at 8:30 AM EDT NEW YORK, May 13, 2024 - PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the |
|
| May 13, 2024 |
Exhibit 10.4 AMENDMENT AND WAIVER This Amendment and Waiver (this “Agreement”) is entered into as of March 12, 2024 (the “Effective Date”), by and between PAVmed Inc., a Delaware corporation with offices located at 360 Madison Avenue, 25th Floor, New York, NY 10017 (the “Company”) and the investor signatory hereto (the “Investor”), with reference to the following facts: A. The Company and the Inve |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2024 PAVMED INC. |
|
| May 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2024 PAVMED INC. |
|
| May 1, 2024 |
Exhibit 99.1 PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK, April 30, 2024 – PAVmed Inc. (Nasdaq: PAVM) (“PAVmed” or the “Company”) a diversified commercial-stage medical technology comp |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2024 PAVMED INC. |
|
| March 25, 2024 |
Exhibit 21.1 List of Subsidiaries of the Registrant (PAVmed Inc. DE - 47-1214177) Subsidiary Legal Entity Name State of Incorporation Lucid Diagnostics Inc. (82-5488042) Delaware - Majority-Owned Subsidiary of PAVmed Inc. (Incorporated May 8, 2018) LucidDx Labs Inc. (87-41661458) Delaware - Wholly-Owned Subsidiary of Lucid Diagnostics Inc. (Incorporated November 10, 2021) Veris Health Inc. (87-098 |
|
| March 25, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, PAVmed Inc. (“PAVmed,” the “Company” or “we,” “us” or “our”) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share; and (ii) |
|
| March 25, 2024 |
Form of Compensation Clawback Policy Exhibit 97.1 PAVMED INC. COMPENSATION CLAWBACK POLICY Effective as of January 30, 2024 Introduction The Board of Directors (the “Board”) of PAVmed Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosoph |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2024 PAVMED INC. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2024 PAVMED INC. |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2024 PAVMED INC. |
|
| February 20, 2024 |
LUCD / Lucid Diagnostics Inc. / PAVmed Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2024 PAVMED INC. |
|
| February 14, 2024 |
PAVM / PAVmed Inc. / Ayrton Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2024 PAVMED INC. |
|
| February 9, 2024 |
360 Madison Avenue, 25th Floor New York, New York 10017 Exhibit 99.1 360 Madison Avenue, 25th Floor New York, New York 10017 February 9, 2024 Dear PAVmed Inc. Stockholders: On November 28, 2023, the board of directors of PAVmed Inc. (NASDAQ: PAVM) (“PAVmed”) approved a distribution by special dividend to PAVmed’s stockholders of approximately 3,331,771 shares of common stock of Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid Diagnostics”) held by PAVmed. |
|
| February 6, 2024 |
Calculation of Filing Fee Table (filed herewith) EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity 2014 Long-Term Incentive Equity Pl |
|
| February 6, 2024 |
As filed with the Securities and Exchange Commission on February 6, 2024 S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on February 6, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PAVMED INC. (Exact name of registrant as specified in its charter) Delaware 47-1214177 (State or other jurisdiction of (I.R.S. Employer incorporation or |
|
| February 6, 2024 |
As filed with the Securities and Exchange Commission on February 6, 2024 As filed with the Securities and Exchange Commission on February 6, 2024 Registration No. |
|
| February 6, 2024 |
Calculation of Filing Fee Table (filed herewith) EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Employee Stock Purchase Plan Commo |
|
| February 2, 2024 |
LUCD / Lucid Diagnostics Inc. / PAVmed Inc. Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Lucid Diagnostics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 54948X 109 (CUSIP Number) Lishan Aklog, M.D. Chairman and Chief Executive Officer, PAVmed Inc. 360 Madison Avenue, 2 |
|
| January 30, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2024 PAVMED INC. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2024 PAVMED INC. |
|
| December 5, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF PAVMED INC. —————————————————- Pursuant to Section 242 of the General Corporation Law of Delaware —————————————————- The undersigned Chairman of the Board and Chief Executive Officer of PAVmed Inc. (the “Corporation”) does hereby certify: FIRST: The name of the Corporation is PAVmed Inc. SECOND: Upon the Effective Time (as def |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 PAVMED INC. |
|
| December 5, 2023 |
Exhibit 99.1 PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be effective as of market open on December 7, 2023 NEW YORK, December 4, 2023 - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Compa |
|
| November 15, 2023 |
Exhibit 99.1 PAVmed Provides Business Update and Third Quarter Financial Results Lucid’s quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conference call and webcast to be held tomorrow, November 15th at 8:30 AM EST NEW YORK, November 14, 2023 - PAVmed Inc. (NASDAQ: PAVM, PAVMZ) |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 PAVMED INC. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2023 PAVMED INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2023 PAVMED INC. |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2023 PAVMED INC. |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2023 PAVMED INC. |
|
| May 30, 2023 |
Up to $18,000,000 Common Stock Amendment No. 1 Filed pursuant to Rule 424(b)(5) (to Prospectus Supplement dated January 7, 2022 Registration No. 333-261814 to Prospectus dated January 7, 2022) Up to $18,000,000 Common Stock This amendment no. 1, or this “Amendment,” amends our prospectus supplement dated January 7, 2022, or the “Prospectus Supplement.” This Amendment should be read in conjunction with the Prospectus Supplement |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2023 PAVMED INC. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2023 PAVMED INC. |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2023 PAVMED INC. |
|
| March 15, 2023 |
Exhibit 99.1 PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST NEW YORK, March 14, 2023 - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital healt |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 PAVMED INC. |
|
| March 14, 2023 |
Form of Stock Option Agreement Exhibit 10.12 PAVMED INC. 2014 LONG-TERM INCENTIVE EQUITY PLAN STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT is made as of the Grant Date by and between PAVmed Inc., a Delaware corporation (the “Company”), and Grantee. WHEREAS, pursuant to the terms and conditions of the Company’s 2014 Long-Term Incentive Equity Plan (the “Plan”), the Compensation Committee (the “Committee”) of the Board of D |
|
| March 14, 2023 |
Exhibit 21.1 List of Subsidiaries of the Registrant (PAVmed Inc. DE - 47-1214177) Subsidiary Legal Entity Name State of Incorporation Lucid Diagnostics Inc. (82-5488042) Delaware - Majority-Owned Subsidiary of PAVmed Inc. (Incorporated May 8, 2018) LucidDx Labs Inc. (87-41661458) Delaware - Wholly-Owned Subsidiary of Lucid Diagnostics Inc. (Incorporated November 10, 2021) Veris Health Inc. (87-098 |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| March 14, 2023 |
Exhibit 14.1 PAVMED INC. CODE OF ETHICS 1. Introduction The Board of Directors of PAVmed Inc. has adopted this code of ethics (the “Code”), which is applicable to all directors, officers and employees, to: ● promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; ● promote the full, fair, accura |
|
| March 14, 2023 |
Form of Indemnification Agreement Exhibit 10.13 INDEMNIFICATION AGREEMENT This Agreement, made and entered into effective as of [] (“Agreement”), by and between PAVmed Inc., a Delaware corporation (“Company”), and the undersigned indemnitee (“Indemnitee”). WHEREAS, the Board of Directors of the Company (“Board”) has determined that the ability to attract and retain qualified officers and directors is in the best interests of the C |
|
| March 14, 2023 |
Employment Agreement between PAVmed Inc. and Michael A. Gordon Exhibit 10.9 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of April 18. 2022 is entered into between Michael Gordon (“Executive”), and PAVmed Inc., a Delaware corporation having its principal office at One Grand Central Place, Suite 4600, New York, New York 10165 (“Company”) to become effective immediately. WHEREAS, the Company and the Executive desire to ente |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 PAVMED INC. |
|
| March 14, 2023 |
Description of Registrant’s Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, PAVmed Inc. (“PAVmed,” the “Company” or “we,” “us” or “our”) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share; and (ii) |
|
| March 14, 2023 |
Exhibit 10.14.2 TERMINATION AGREEMENT This Termination Agreement (this “Termination Agreement”) is entered as of February 10, 2023 (the “Effective Date”), by and among ResearchDx, Inc., a California corporation (“ResearchDx”), Lucid Diagnostics Inc., a Delaware corporation (“Lucid Diagnostics”), and LucidDx Labs Inc., a Delaware corporation (“LucidDx Labs”). Each of ResearchDx, Lucid Diagnostics a |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2023 PAVMED INC. |
|
| February 21, 2023 |
Form of Certificate of Amendment.(1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 PAVMED INC. |
|
| February 16, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2023 PAVMED INC. |
|
| February 16, 2023 |
Exhibit 99.1 Lucid Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event Partners with San Antonio Fire Department to test nearly 400 firefighters for esophageal precancer during Firefighter Cancer Awareness Month over two weekends, averaging nearly 100 tests per day Expands utilization of satellite Lucid Test Centers in support of National Cancer Prevention Month NEW YORK, February 1 |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 10, 2023 |
Calculation of Filing Fee Table (filed herewith) EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity 2014 Long-Term Incentive Equity Pl |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 10, 2023 |
Calculation of Filing Fee Table (filed herewith) EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Employee Stock Purchase Plan Commo |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 18, 2023 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PAVmed and Lucid Diagnostics Provide Strategic Business Update Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercialization efforts Conference call to be held today at 4:30PM EDT NEW YORK, January 17, 2023 — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversifie |
|
| January 18, 2023 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 17, 2023 PAVMED INC. |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2022 PAVMED INC. |
|
| December 2, 2022 |
AT:VLA / Common Stock / PAVmed Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2022 PAVMED INC. |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2022 PAVMED INC. |
|
| November 15, 2022 |
Exhibit 99.1 PAVmed Provides Business Update and Third Quarter 2022 Financial Results EsoGuard test volume shows steady sequential growth Veris Cancer Care Platform poised for commercial launch Conference call and webcast to be held today at 4:30 PM EDT NEW YORK, November 15, 2022 (BUSINESS WIRE) —PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2022 PAVMED INC. |
|
| September 9, 2022 |
Exhibit 10.3 AMENDMENT AND WAIVER This Amendment and Waiver (this ?Agreement?) is entered into as of September 8, 2022 (the ?Effective Date?), by and between PAVmed Inc., a Delaware corporation with offices located at One Grand Central Place, Suite 4600, New York, NY 10165 (the ?Company?) and the investor signatory hereto (the ?Investor?), with reference to the following facts: A. The Company and |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2022 PAVMED INC. |
|
| August 17, 2022 |
Exhibit 99.1 PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results Lucid?s EsoGuard test volume grows 60% and LucidDx Labs fully operational Veris Health Cancer Care Platform to commercially launch this year Conference call to be held today at 4:30 PM EDT NEW YORK, August 16, 2022 (BUSINESS WIRE) ?PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a dive |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2022 PAVMED INC. |
|
| June 22, 2022 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF PAVMED INC. Pursuant to Section 242 of the General Corporation Law of Delaware The undersigned Chairman and Chief Executive Officer of PAVmed Inc. (the ?Corporation?) does hereby certify: FIRST: The name of the Corporation is PAVmed Inc. SECOND: The certificate of incorporation of the Corporation is hereby amended by deleting |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2022 PAVMED INC. |
|
| May 12, 2022 |
Exhibit 99.1 PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results Conference call to be held today at 4:30 PM EDT NEW YORK, May 12, 2022 (BUSINESS WIRE) ?PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a b |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2022 PAVMED INC. |
|
| April 26, 2022 |
PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit Exhibit 99.2 PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit NEW YORK, April 26, 2022 (Business Wire) ?PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit. As previously disclos |
|
| April 26, 2022 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE George A. Spritzer, on behalf of himself and all other similarly situated stockholders, Plaintiff, v. LISHAN AKLOG, RONALD M. SPARKS, DAVID S. BATTLEMAN, M.D., JAMES L. COX, DAVID WEILD IV, MICHAEL J. GLENNON, and PAVMED INC. Defendants, ) ) ) ) ) ) ) ) ) ) ) ) ) ) C.A. No. 2020-0935-KSJM NOTICE OF PENDENCY OF CLASS ACTION, PROPOSED SE |
|
| April 22, 2022 |
PRE 14A 1 pre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| April 13, 2022 |
As filed with the Securities and Exchange Commission on April 13, 2022 As filed with the Securities and Exchange Commission on April 13, 2022 Registration No. |
|
| April 13, 2022 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity 2014 Long-Term Incentive Equity Pl |
|
| April 13, 2022 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) PAVmed Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Employee Stock Purchase Plan Commo |
|
| April 13, 2022 |
As filed with the Securities and Exchange Commission on April 13, 2022 S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on April 13, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PAVMED INC. (Exact name of registrant as specified in its charter) Delaware 47-1214177 (State or other jurisdiction of incorporation or organization) (IRS |
|
| April 6, 2022 |
Description of Registrant’s Securities † Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, PAVmed Inc. (?PAVmed,? the ?Company? or ?we,? ?us? or ?our?) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (i) common stock, $0.001 par value per share; (ii) Seri |
|
| April 6, 2022 |
Exhibit 21.1 List of Subsidiaries of the Registrant (PAVmed Inc. DE - 47-1214177) Subsidiary Legal Entity Name State of Incorporation Lucid Diagnostics Inc. (82-5488042) Delaware - Majority-Owned Subsidiary of PAVmed Inc. (Incorporated May 8, 2018) LucidDx Labs Inc. (87-41661458) Delaware - Wholly-Owned Subsidiary of Lucid Diagnostics Inc. (Incorporated November 10, 2021) Veris Health Inc. (87-098 |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVMED INC. |
|
| April 4, 2022 |
Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of March 31, 2022, is by and among PAVmed Inc., a Delaware corporation with offices located at One Grand Central Place, Suite 4600, New York, NY 10165 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and collectively, the ?Buy |
|
| April 4, 2022 |
Exhibit 10.2 SECURITY AND PLEDGE AGREEMENT SECURITY AND PLEDGE AGREEMENT, dated as of April 4, 2022 (this ?Agreement?), made by PAVmed Inc., a Delaware corporation with offices located at One Grand Central Place, Suite 4600, New York, NY 10165 (the ?Company?), and each of the undersigned direct and indirect Significant Subsidiaries of the Company from time to time, if any (each a ?Grantor? and tog |
|
| April 4, 2022 |
Form of PAVmed Inc. Senior Secured Convertible Note EXHIBIT 4.1 THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 3(c)(iii) OF THIS NOTE. THIS NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT (?OID?). PURSUANT TO TREASURY REGULATION ?1.1275-3(b)(1), DENNIS MCGRATH, A REPRESENTATIVE OF THE COMPANY HEREOF WILL, B |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2022 PAVMED INC. |
|
| April 4, 2022 |
EXHIBIT 10.3 VOTING AGREEMENT VOTING AGREEMENT, dated as of April 4, 2022 (this ?Agreement?), by and between PAVmed Inc., a Delaware corporation with offices located at One Grand Central Place, Suite 4600, New York, NY 10165 (the ?Company?) and [] (the ?Stockholder?). WHEREAS, the Company and certain investors (each, an ?Investor?, and collectively, the ?Investors?) have entered into a Securities |
|
| April 4, 2022 |
The date of this prospectus supplement is March 31, 2022. TABLE OF CONTENTS PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 7, 2022) Registration No. |
|
| April 4, 2022 |
Exhibit 99.1 Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination Updated American College of Gastroenterology clinical guideline supports esophageal precancer screening with EsoGuard? on samples collected with EsoCheck? Proposed Medicare Local Coverage Determination published by Palmetto GBA?s MolDX Progra |
|
| April 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2022 PAVMED INC. |
|
| April 1, 2022 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . . . . 3235-0058 Washington, D.C. 20549 Expires: . . . . . . . February 28, 2022 Estimated average burden Hours per form. . . . . . . . . . . . . . 2.50 FORM 12b-25 SEC FILE NUMBER 001-37685 NOTIFICATION OF LATE FILING CUSIP NUMBER 70387R 106 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2022 PAVMED INC. |
|
| March 29, 2022 |
Exhibit 99.1 PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results Conference call to be held today at 4:30 PM EDT NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, |
|
| March 8, 2022 |
Exhibit 99.1 PAVmed to Hold a Business Update Conference Call on March 29, 2022 Company conference call and webcast at 4:30 PM EDT NEW YORK, March 8, 2022 (BUSINESS WIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on Tuesday, March 29, 2022, at 4: |
|
| March 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2022 PAVMED INC. |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2022 PAVMED INC. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2022 PAVMED INC. |
|
| February 24, 2022 |
Employment Agreement between PAVmed Inc. and Shaun M. O’Neil Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of February 22, 2022 is entered into between Shaun O?Neil (?Executive?), and PAVmed Inc., a Delaware corporation having its principal office at One Grand Central Place, Suite 4600, New York, New York 10165 (?Company?) to become effective immediately. WHEREAS, the Company and the Executive desire to ent |
|
| February 24, 2022 |
PAVmed Appoints Shaun O’Neil as Chief Operating Officer Exhibit 99.1 PAVmed Appoints Shaun O’Neil as Chief Operating Officer NEW YORK, February 24, 2022 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of Shaun O’Neil to serve as Executive Vice |
|
| February 15, 2022 |
Exhibit 99.1 Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors NEW YORK, February 15, 2022 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (?Lucid?), today announced the app |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2022 PAVMED INC. |
|
| January 10, 2022 |
Up to $50,000,000 Common Stock 424B5 1 form424b5.htm Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration No. 333-261814 Up to $50,000,000 Common Stock We have entered into a Controlled Equity Offering℠ Sales Agreement, or the “sales agreement,” with Cantor Fitzgerald & Co., or “Cantor Fitzgerald,” relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the ac |
|
| January 5, 2022 |
PAVMED INC. One Grand Central Place, Suite 4600 New York, New York 10165 PAVMED INC. One Grand Central Place, Suite 4600 New York, New York 10165 January 5, 2022 Securities and Exchange Commission Division of Corporation Finance Washington, District of Columbia 20549 Re: PAVmed Inc. Registration Statement on Form S-3 Filed December 21, 2021 File No. 333-261814 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, PAVmed In |
|
| December 21, 2021 |
EX-1.2 2 ex1-2.htm Exhibit 1.2 PAVMED INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement December 21, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: PAVmed Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Issuanc |
|
| December 21, 2021 |
As filed with the Securities and Exchange Commission on December 21, 2021 As filed with the Securities and Exchange Commission on December 21, 2021 Registration No. |
|
| December 21, 2021 |
Form of Indenture for Senior Debt Securities between the Registrant and Trustee to be designated. Exhibit 4.6 PAVMED INC., As Issuer, AND [], As Trustee INDENTURE DATED AS OF [] [], 20[] SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Indenture 310(a) 7.10 310(b) 7.09; 7.11 310(c) Inapplicable 311(a) 7.14 311(b) 7.14 311(c) Inapplicable 312(a) 5.02(a) 312(b) 5.02(c) 312(c) Inapplicable 313(a) 5.04(a) 313(b) 5.04(b) 313(c) 5.04(a); 5.04(b) 313 |
|
| December 21, 2021 |
Exhibit 4.7 PAVMED INC., As Issuer, AND , As Trustee INDENTURE DATED AS OF [] [], 20[] SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Indenture 310(a) 7.10 310(b) 7.09; 7.11 310(c) Inapplicable 311(a) 7.14 311(b) 7.14 311(c) Inapplicable 312(a) 5.02(a) 312(b) 5.02(c) 312(c) Inapplicable 313(a) 5.04(a) 313(b) 5.04(b) 313(c) 5.04(a); 5.04(b) |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVmed Inc. |
|
| November 16, 2021 |
NT 10-Q 1 formnt10-q.htm UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . .3235-0058 Washington, D.C. 20549 Expires: . . . . . . February 28, 2022 Estimated average burden Hours per form. . . . . . . . 2.50 FORM 12b-25 SEC FILE NUMBER 001-37685 NOTIFICATION OF LATE FILING CUSIP NUMBER 70387R 106 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ |
|
| November 4, 2021 |
Exhibit 99.1 PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021 Company conference call and webcast at 4:30PM EDT NEW YORK, November 3, 2021 (BUSINESS WIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical |
|
| November 4, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2021 PAVMED INC. |
|
| October 27, 2021 |
US54948X1090 / COMMON STOCK / PAVmed Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 25, 2021 |
PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer Exhibit 99.1 PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer NEW YORK, October 25, 2021?(BUSINESS WIRE)? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (?PAVmed?), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (?Veris?) today announced the appointment of Silicon Valley technology |
|
| October 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2021 PAVMED INC. |
|
| October 18, 2021 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 18, 2021 PAVMED INC. |
|
| October 7, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2021 PAVMED INC. |
|
| October 7, 2021 |
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC Exhibit 99.1 PAVmed Acquires EsophaCap Manufacturer CapNostics LLC NEW YORK, October 7, 2021 (BUSINESS WIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Vo |
|
| October 6, 2021 |
PAVM / PAVmed Inc / SIROVICH MATTHEW Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* PAVmed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 70387R106 (CUSIP Number) October 4, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVmed Inc. |
|
| August 12, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 PAVMED INC. |
|
| August 12, 2021 |
Exhibit 99.1 PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results Conference call to be held today at 4:30 PM EDT NEW YORK, Aug. 12, 2021 (BUSINESS WIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its major subs |
|
| August 10, 2021 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2021 PAVMED INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37685 47-1214177 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2021 |
Exhibit 99.1 PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers Patients undergoing esophageal precancer testing at centers in Phoenix metro area NEW YORK, August 10, 2021 (BUSINESSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its majority owned subs |
|
| August 4, 2021 |
As filed with the Securities and Exchange Commission on August 4, 2021 As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. |
|
| August 4, 2021 |
As filed with the Securities and Exchange Commission on August 4, 2021 As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. |
|
| August 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2021 PAVMED INC. |
|
| August 3, 2021 |
Exhibit 99.1 Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics? Board of Directors NEW YORK, August 03, 2021 (BUSINESSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that prominent global industry executive Aster Angagaw has joined the Board of |
|
| July 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2021 PAVMED INC. |
|
| July 28, 2021 |
Exhibit 99.1 Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors NEW YORK, July 28, 2021 (BUSINESSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that medical diagnostics pi |
|
| July 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 22, 2021 PAVMED INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37685 47-1214177 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 23, 2021 |
Exhibit 99.1 PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth UpScriptHealth to provide telemedicine services to evaluate consumers with chronic heartburn seeking early esophageal precancer detection using Lucid?s EsoGuard test NEW YORK, July 22, 2021 (BUSINESSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ? |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 PAVMED INC. |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2021 PAVMED INC. |
|
| June 14, 2021 |
Exhibit 99.1 Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology ind |
|
| June 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2021 PAVMED INC. |
|
| June 10, 2021 |
Exhibit 99.1 PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (?PAVmed?), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (?Lucid?), has completed European IVDD |
|
| June 2, 2021 |
Exhibit 99.1 PAVmed Launches Digital Health Company Veris Health Inc. New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. Technologies include first intelligent implantable vascular access port with biologic sensors and wireless communication combined with remote oncology digital healthcare platform NEW YORK, June 2, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasda |
|
| June 2, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2021 PAVMED INC. |
|
| May 26, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2021 PAVMED INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37685 47-1214177 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 26, 2021 |
Exhibit 99.1 PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck? Esophageal Cell Collection Device NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (?PAVmed?), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (?Lucid?), today announced that Lucid?s EsoCheck? E |
|
| May 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2021 PAVMED INC. |
|
| May 25, 2021 |
Exhibit 99.1 Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics? EsoCheck and EsoGuard Technologies Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (?PAVmed?), a highly |
|
| May 25, 2021 |
Exhibit 99.2 PAVmed Receives European CE Mark Certification for its CarpX? Minimally Invasive Carpal Tunnel Device NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its CarpX? minimally invasive carpal |
|
| May 20, 2021 |
PAVmed Inc. Fourth Amended and Restated 2014 Long-Term Incentive Equity Plan EXHIBIT 10.1 PAVmed Inc. Fourth Amended and Restated 2014 Long-Term Incentive Equity Plan Section 1.?Purpose; Definitions. 1.1.?Purpose.?The purpose of the PAVmed Inc. 2014 Long-Term Incentive Equity Plan (?Plan?) is to enable the Company to offer to its employees, officers, directors and consultants whose past, present and/or potential future contributions to the Company and its Subsidiaries have |
|
| May 20, 2021 |
As filed with the Securities and Exchange Commission on May 20, 2021 As filed with the Securities and Exchange Commission on May 20, 2021 Registration No. |
|
| May 20, 2021 |
Form of Restricted Stock Agreement (filed herewith). EXHIBIT 10.3 RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT is made as of the [?] day of [?], [?] (the ?Grant Date?) by and between PAVmed Inc., a Delaware corporation (the ?Company?), and [?] (?Grantee?). WHEREAS, pursuant to the terms and conditions of the Company?s 2014 Long-Term Incentive Equity Plan, as amended (the ?Plan?), the Compensation Committee (the ?Committee?) of the Boar |
|
| May 20, 2021 |
Form of Stock Option Agreement (filed herewith). EXHIBIT 10.2 STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT is made as of the th day of , 2021 (the ?Grant Date?) by and between PAVmed Inc., a Delaware corporation (the ?Company?), (?Grantee?). WHEREAS, pursuant to the terms and conditions of the Company?s 2014 Long-Term Incentive Equity Plan (the ?Plan?), the Compensation Committee (the ?Committee?) of the Board of Directors of the Company ( |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37685 PAVmed Inc. |
|
| May 17, 2021 |
Exhibit 99.1 PAVmed Provides Business Update and First Quarter 2021 Financial Results Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ?Company? or ?PAVmed?), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its major subsidiary, Lucid |
|
| May 17, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2021 PAVMED INC. |
|
| May 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2021 PAVMED INC. |
|
| May 13, 2021 |
Exhibit 99.1 PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021 Dr. David Poppers to present on his initial experience with Lucid?s EsoCheck and EsoGuard NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (?PAVmed? or the ?Company?), a highly differentiated, multi-product, commercial-stage medical technology company, and its |
|
| May 6, 2021 |
Exhibit 99.1 PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization NEW YORK, May 6, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (?PAVmed? or the ?Company?), a highly differentiated, multi-product, commercial-stage medical technology company, today announced tha |
|
| May 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 PAVMED INC. |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| April 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2021 PAVMED INC. |
|
| April 29, 2021 |
Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors Exhibit 99.1 Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics? Board of Directors NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) ? PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (?PAVmed?), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (?Lucid? or the ?Company?) has appointed nationally recognized hea |
